Skip to search formSkip to main contentSkip to account menu

AXL1717

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Purpose Early phase I study of safety of AXL1717 in patients with recurrent or progressive malignant astrocytomas and evaluation… 
2017
2017
Abstract Background: The primary objective of this study was to compare the progression-free survival (PFS) at 12 weeks between… 
2017
2017
Background: The aim of the present study was to investigate any prognostic value of pre-treatment anemia, leukocytosis and… 
2015
2015
Abstract AXL1717 is an orally bioavailable IGF-1R pathway modulator that has been shown to have anti-tumoral effects. The… 
2014
Highly Cited
2011
Highly Cited
2011
Abstract Background. Inhibition of the Insulin-like Growth Factor-1 receptor (IGF-1R) has resulted in extensive anti-tumor… 
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background The incidence of lung cancer has increased… 
2010
2010
e13019 Background: Inhibition of the insulin-like growth factor-1 receptor (IGF-1R) has resulted in extensive antitumor effects…